[Latin Name] Linum Usitatissimum L.

[Plant Source] from China

[Specifications]SDG20% 40% 60%

[Appearance] yellow brown powder

Plant Part Used:Seed

[Particle size] 80 Mesh

[Loss on drying] ≤5.0%

[Heavy Metal] ≤10PPM

[Storage] Store in cool & dry area, keep away from the direct light and heat.

[Shelf life] 24 Months

[Package] Packed in paper-drums and two plastic-bags inside.

[Net weight] 25kgs/drum

Product description:

Flaxseed extract is a kind of plant ligan most notably found in flaxseed. Secoisolariciresinol diglycoside, or SDG is existed as its main bioactive components. SDG is classified as a phytoestrogen since it is a plant-derived, nonsteroid compound that possesses estrogen-like activity. Flaxseed extract  SDG has weak estrogenic activity, when intake as food it will be trasfer to flax ligan which have same structure with estrogens.The level of SDG in flaxseed typically varies between 0.6% and 1.8%. Flaxseed extract powder SDG can reduce the blood lipid, cholesterin and triglyceride, it can also prevent for apoplexy, hyperension, blood clots, arteriosclerosis and arrhythmia. In addition, flax seed extract powder SDG is benificial for diabetes and CHD.

Main Function:

1.Flaxseed extract used to lose weight. Can burn surplus fat of Body;

2.Flaxseed extract will reduce allergic reaction, reduce asthma, improve arthritis;

3.Flaxseed extract with the function of improving female menstrual period syndrome;

4.Flaxseed extract can reduce the bad influence of hazardous chemicals produced when under pressure, control Stress, reduce depression and insomnia;

5.Flaxseed extract will improve skin fat content, moisten the skin smooth, soft and flexible, make the skin breath and sweat to normal, to mitigate various skin problems.

hahaha huli kang loko ka!

To get this product go to: https://www.camellix.com

AUGUSTA, Ga. — An over-the-counter lozenge containing green tea antioxidants could significantly enhance oral health and quality of life for millions of patients suffering from dry mouth, researchers at Georgia Regents University have found.

The MighTeaFlow® formula, developed by professionals in the GRU College of Dental Medicine, produces a four-fold increase in saliva, according to clinical trial data. The findings and the MighTeaFlow line of products, which include a chewing gum, rinse, oral spray, and the lozenges used in the study, prove that the products works, said Dr. Scott DeRossi, Chairman of Oral Health and Diagnostic Sciences in the College of Dental Medicine. The formula, DeRossi said, “increases a patient’s salivary flow statistically and clinically to a significant level without any adverse side effects.”
DeRossi and Dr. Stephen Hsu, Professor of Oral Biology in the College of Dental Medicine, co-authors of the study, presented their findings on April 10 at Frontiers in Oral Medicine 2014, an international gathering of oral medicine professionals in Orlando, Fla.

Dry mouth affects up to half of all elderly adults in the United States, and is a common side effect of cancer treatments, some medications, and autoimmune diseases such as Sjogren’s syndrome.

Researchers asked 60 patients with dry mouth symptoms to consume one lozenge every four hours. Half received lozenges containing the patented MighTeaFlow formula, and the other half received a placebo containing 500 milligrams of xylitol. After eight weeks, the group receiving the active lozenges experienced a 419 percent increase in “unstimulated” saliva production, such as while resting or sleeping. The same group also experienced a 218 percent increase in “stimulated” saliva production, such as while chewing. The group receiving the placebo experienced no significant change in saliva production.

“The results are dramatic. You look at the data and immediately go, ‘This has a huge clinical impact for patients,” DeRossi said. “This is unlike other products on the market. When patients go to the drug store or get recommendations from their dentists, those products are only designed to make their mouths more comfortable.”

DeRossi said other products just treat the symptoms, but MighTeaFlow actually addresses the problem. “Our formula results in the partial restoration of salivary function. What’s more, we’re finding that this product could actually delay disease progression.”

MighTeaFlow products contain the green tea compound EGCG (epigallocatechin-3-gallate), which protects salivary gland cells from inflammation, and other natural botanical extracts that have been used for centuries by native South Americans to increase fluid secretions. The formula has more than a decade of research behind it, said Hsu, whose start-up biotechnology and drug development company Camellix, LLC, markets the products.

All four dry mouth products were developed and patented at the GRU Life Sciences Business Development Center in the Office of Innovation Commercialization, a unit that takes research from the laboratory to the marketplace.

“An interdisciplinary team made this happen,” Hsu said. “The right team came together with complimentary areas of expertise. Without the support for translational study from the state and the university, we wouldn’t have been able to develop these revolutionary products. We were encouraged to go all the way from molecules to prescription drugs, from the lab to the bedside.”

The findings warrant further research in large-scale clinical trials that could eventually lead to the development of new prescription drugs based off the MighTeaFlowformula, according to the researchers.

The trial was supported in part by an International Association for Dental Research and GlaxoSmithKline Innovation in Oral Care Award and a grant from the Georgia Research Alliance. For more information on research, publications, and MighTeaFlow products, visit www.camellix.com or call 888-483-7775.